文献速递神经肿瘤

1型神经纤维瘤病儿童视路胶质瘤治疗难治与复发的危险因素

Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1.
PubMed 文献 · Neuro Oncol · 2022-01-01

该回顾性多机构队列研究纳入103例1型神经纤维瘤病相关视路胶质瘤(NF1-OPG)患儿,分析治疗难治/复发及视力不良的基线危险因素。44%患儿出现难治/复发,初始治疗年龄小于24个月、肿瘤位于后部及家族遗传与2年内难治/复发相关。后部肿瘤、视盘异常或初始视力异常与末次随访中重度视力丧失相关。

要点

  • 44%的NF1-OPG患儿出现治疗难治/复发,中位至二次治疗时间21.5个月。
  • 初始治疗年龄小于24个月、后部肿瘤位置和家族遗传与2年内难治/复发相关。
  • 后部肿瘤位置、视盘异常或初始视力异常与末次随访中重度视力丧失相关。

核心结论

  • 年幼、肿瘤位于后部及视盘异常可能识别出最可能出现难治/复发NF1-OPG和视力不良的患者,这些患者可能受益于更新的治疗策略。

研究设计与样本

  • 回顾性多机构队列研究,纳入来自7个机构的103例有足够临床和视力数据的NF1-OPG患儿(共111例符合纳入标准)。
  • 难治/复发NF1-OPG定义为因进展或复发需要两种或以上治疗方案。
  • 自首次化疗方案开始的中位随访时间为95个月(范围13-185)。

主要发现

  • 84例(82%)受试者接受以卡铂为基础的一线化疗。
  • 45例(44%)受试者发生难治/复发疾病,从首次治疗开始至第二次治疗开始的中位时间为21.5个月(范围2-149)。
  • 2年和5年无难治/复发疾病的患者比例分别为78%和60%。
  • 多变量分析中,初始治疗时年龄小于24个月、肿瘤位于后部及家族遗传与2年内难治/复发NF1-OPG相关。
  • 年龄小于24个月和肿瘤位于后部均与5年内难治/复发NF1-OPG相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nearly one-third of patients with neurofibromatosis type 1-associated optic pathway glioma (NF1-OPG) fail frontline chemotherapy; however, little is known about risk factors for treatment failure. METHODS: We performed a retrospective multi-institutional cohort study to identify baseline risk factors for treatment-refractory/relapsed disease and poor visual outcome in children with NF1-OPG. Refractory/relapsed NF1-OPG was defined as a requirement of two or more treatment regimens due to progression or relapse. RESULTS: Of 111 subjects eligible for inclusion, adequate clinical and visual data were available for 103 subjects from 7 institutions. Median follow-up from the initiation of first chemotherapy regimen was 95 months (range 13-185). Eighty-four (82%) subjects received carboplatin-based frontline chemotherapy. Forty-five subjects (44%) experienced refractory/relapsed disease, with a median time of 21.5 months (range 2-149) from the initiation of first treatment to the start of second treatment. The proportion of patients without refractory/relapsed disease at 2 and 5 years was 78% and 60%. In multivariable analyses, age less than 24 months at initial treatment, posterior tumor location, and familial inheritance were associated with refractory/relapsed NF1-OPG by 2 years. Both age less than 24 months and posterior tumor location were associated with refractory/relapsed NF1-OPG by 5 years. Subjects with moderate to severe vision loss at last follow-up were more likely to have posterior tumor location, optic disc abnormalities, or abnormal visual acuity at initial treatment. CONCLUSION: Young age, posterior tumor location, and optic disc abnormalities may identify patients with the greatest likelihood of refractory/relapsed NF1-OPG and poor visual outcomes, and who may benefit from newer treatment strategies.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Kotch C, Avery R, Getz KD, et al. Risk factors for treatment-refractory and relapsed optic pathway glioma in children with neurofibromatosis type 1. Neuro Oncol. 2022. PMID: 35018469. doi:10.1093/neuonc/noac013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。